Digital First, Faster Access: How TB Alliance Is Using Tech to Speed BPaL/M to People Who Need It
For decades, breakthrough TB science has too often moved slowly from approval to those in need. In the roll out
Access News
TB Alliance Launches Upskill TB Platform in Collaboration with Indonesia’s Ministry of Health and RPRI Foundation
Digital Training Platform, Upskill TB, Strengthens Capacity to Deliver New DR-TB Treatments JAKARTA (October 9, 2025)—TB Alliance, in collaboration with
DR-TB Regimen Will Save 190,000+ Additional Lives and $1.29B by 2035
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing the trajectory of DR-TB care
New Study Finds Investing in Shorter, More Effective TB Treatment Pays Off
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms that six-month, all-oral BPaL/M regimens
TB Alliance Welcomes WHO Prequalification of Lupin’s Pretomanid Product
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been granted prequalification by the World
Bangladesh TB Leaders Build Momentum for Shorter, Safer Drug-Resistant Tuberculosis Treatment
Capacity building program in the Philippines empowers Bangladesh NTP managers to scale up BPaL and BPaL/M regimens MAKATI CITY, PHILIPPINES—PeerLINC
New Study Affirms Financial and Public Health Advantages of Treating Drug-Resistant TB with BPaL-Based Regimens in India
A new economic evaluation has added powerful evidence to the already strong case for wide, global adoption of BPaL and
TB Alliance’s DR-TB Treatment Rollout Recognized by WHO as Model for Responsible & Effective Antibiotic Introduction
The World Health Organization’s (WHO) new guidance on Country Preparedness for the Introduction and Appropriate Use of Antibiotics highlighted TB
TB Experts Rally Around New, Shortened TB Treatments
Regional meeting in Peru convened by PeerLINC, a global peer-to-peer initiative, brings together 20 countries to accelerate collaboration and scale-up
Price of Key DR-TB Medicine Drops 25% as TB Alliance’s Multi-Manufacturer Strategy Expands Access
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access TB Alliance